Basic information Safety Related Supplier

ChemicalBook Product Catalog API Anesthetic Agents Local anesthetics Ropivacaine hydrochloride monohydrate

1/1

Ropivacaine hydrochloride monohydrate NEW

$32.00 10mg

$48.00 25mg

$72.00 50mg

Min. Order
Purity99.80%
Cas No132112-35-7
Supply Ability10g
Update time2024-11-19

TargetMol Chemicals Inc.

TargetMol Chemicals Inc.

5YR

United States

show more

Chemical Properties

Product Name	Ropivacaine hydrochloride monohydrate
CAS No	132112-35-7
EC-No
Min. Order
Purity	99.80%
Supply Ability	10g
Release date	2024/11/19

Product Introduction

Bioactivity

Name	Ropivacaine hydrochloride monohydrate
Description	Ropivacaine hydrochloride monohydrate (LEA-103 HCl) is an anaesthetic agent and blocks impulse conduction in nerve fibres through inhibiting sodium ion influx reversibly.
In vitro	Raltitrexed induces double-stranded DNA breaks in a concentration-dependent manner. In Lovo cells and LS174T cell lines containing wild-type p53, Raltitrexed increases the levels of the Bax protein up to 5-fold. In human colon cancer cells, Raltitrexed is actively absorbed into cells and is then rapidly and extensively metabolized into a series of polyglutamates, which results in the effective inhibition of thymidylate synthase. Raltitrexed is delivered to the brain very quickly and can be detected in all brain tissues within 5 minutes. In human colon cancer cells, the combination of Raltitrexed and SN-38 results in a synergistic cytotoxic effect within a range of concentrations. Raltitrexed is a specific folate-based inhibitor of thymidylate synthase. The effect on the activity of advanced rectal cancer is similar to fluorouracil (5-fluorouracil) plus leucovorin. Raltitrexed produces activity by rapid cell entry and glutamination. The glutaminated derivatives are more than 100 times more active than the parent compound. In the HCT-8 cell line, Raltitrexed results in an increase in intracellular phosphoribosyl pyrophosphate (PRPD) indicating that the cytotoxic effect of Raltitrexed in combination with 5-FU is due to increased nucleotide formation of 5-FU. Combinations of Raltitrexed and folinic acid (5FU-FA) show a combination of mode-dependent, synergistic inhibition of proliferation, which is determined by measuring the combination series. Raltitrexed combined with Vorinostat produced significant synergistic effects of cell cycle perturbation and S-phase arrest.
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 65 mg/mL (197.64 mM), Sonication is recommended. H2O : 46 mg/mL (147.97 mM)
Keywords	LEA-103 \| Potassium Channel \| hypertension \| Na channels \| pain \| K(2P) \| neuropathic \| Inhibitor \| vasoconstrictive \| KcsA \| Ropivacaine hydrochloride Monohydrate \| Na+ channels \| Ropivacaine HCl Monohydrate \| potassium \| Ropivacaine hydrochloride monohydrate \| Ropivacaine Hydrochloride \| TREK-1 \| Sodium Channel \| inhibit \| conduction \| Ropivacaine hydrochloride \| LEA103 \| channel \| neuronal
Inhibitors Related	Phenytoin sodium \| Lidocaine hydrochloride \| L-Aspartic aicd sodium
Related Compound Libraries	Bioactive Compound Library \| Pain-Related Compound Library \| Drug Repurposing Compound Library \| Neuroprotective Compound Library \| Bioactive Compounds Library Max \| Ion Channel Targeted Library \| Anti-Cancer Drug Library

show more

Company Profile Introduction

You may like

Recommended supplier

MSDS|CAS|CAS DataBase|Pricacy|Terms|About Us|New Products| Contact us|Computer Version
Chemical Book